ALSO NOTED: Bidders line up for Pfizer division; Aspreva gains orphan status; and much more...

> The New York Times is reporting that Pfizer has received a series of bids toping $14 billion for its OTC drugs division. Johnson & Johnson, GSK and Reckitt Benckiser are in the lineup of interested suitors. Report [1]

> Aspreva and Roche have received orphan drug status for CellCept, an experimental therapy for pemphigus vulgaris. CellCept is currently in Phase III. Report [2]

> Canada's YM Biosciences says that an independent monitoring board has asked it to clarify questions about Phase III data for its experimental breast cancer drug tesmilifene. After it receives the information, YM will complete a statistical analysis of the data in several weeks. Report [3]

> Kos Pharmaceuticals has obtained fast track and orphan drug status for Icatibant. Report [4]

> CoTherix has filed a shelf registration to offer up to $80 million in shares. The money will go to develop Ventavis and to acquire new product candidates. Report [5]

> South Korean contract manufacturing organization Celltrion has agreed to provide an equity stake, materials and milestone fees of up to $8.4 million for the Asian rights to a new therapy being developed by A&G Pharmaceuticals. Report [6]

> Croatian drug maker Pliva is expecting binding offers after potential bidders complete the due diligence process in the next few weeks. Report [7]

> Sirtris has announced that it has completed dosing in the first Phase I trial of SRT501--a sirtuin therapeutic. Release [8]

And Finally… Puncturing an old myth, researchers have concluded that male sperm includes a growing concentration of genetic mutations as men age. Report [9]